Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | ABL1 |
| Variant | act mut |
| Impact List | unknown |
| Protein Effect | gain of function |
| Gene Variant Descriptions | ABL1 act mut indicates that this variant results in a gain of function in the Abl1 protein. However, the specific amino acid change has not been identified. |
| Associated Drug Resistance | |
| Category Variants Paths |
ABL1 mutant ABL1 act mut |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02272998 | Phase II | Ponatinib | Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT. | Completed | USA | 0 |
| NCT04501614 | Phase Ib/II | Ponatinib | A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | Terminated | USA | POL | NLD | ITA | GBR | FRA | ESP | CZE | BRA | AUS | ARG | 4 |